drugset
drugset / Trial / NCT07433556

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers

NCT07433556 ↗

Phase 1 Recruiting 86 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blinded, partial-open, placebo/active-controlled, single/multiple dosing, dose escalation phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IY-828026 in healthy adult volunteers

Timeline

Start
2026-03-23
Primary completion
2027-03
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IY-828026 Unknown 10 mg Oral
Subject IY-828026 Unknown 20 mg Oral
Subject IY-828026 Unknown 40 mg Oral
Subject IY-828026 Unknown 80 mg Oral
Subject IY-828026 Unknown 160 mg Oral
Comparator IY-828026A Unknown 40 mg Oral
Comparator IY-828026B Unknown 50 mg Oral

Indications

No indication recorded.